Imani-Musimwa Prince, Grant Emilie, Mukadi-Bamuleka Daniel, Fraterne-Muhayangabo Rigo, Kitenge-Omasumbu Richard, Mbala-Kingebeni Placide, Tsongo-Kibendelwa Zacharie, Nyakio-Ngeleza Olivier, Claris-Mwatsi Ines, Sihali-Kyolov Juakali, Barhwamire-Kabesha Théophile, Kavira-Malengera Celine, Feza-Malira Micheline, Bitwe-Mihanda Richard, Sengeyi-Mushengezi-Amani Dieudonné, Ververs Mija
Department of Obstetrics and Gynecology, School of Medicine, University of Goma, Goma, Democratic Republic of the Congo.
Département de Santé, Centre Régional d'Expertise en Recherche et Actions Humanitaires, Bukavu, Democratic Republic of the Congo.
Case Rep Infect Dis. 2025 Mar 14;2025:2987569. doi: 10.1155/crdi/2987569. eCollection 2025.
Pregnancy induces physiological decline in maternal immunity. Ebola virus disease (EVD) in pregnancy is associated with obstetrical complications, and vaccination in early pregnancy is recommended, but may not be without risk. We described neonatal survival after spontaneous maternal EVD recovery. This neonate was born to a 25-year-old mother admitted to an Ebola Treatment Unit (ETU) in July, 2020, after 11 days of symptoms. She was vaccinated with rVSV-ZEBOV three days before symptom onset and her real-time polymerase chain of reaction (RT-PCR) results confirmed EVD and malarial infection two days after, but she refused hospitalization. She was treated at home with PO ASAQ, amoxicillin, paracetamol, albendazole, omeprazole, and papaverine. Eleven days later, due to clinical deterioration and onset of vaginal hemorrhage, she finally accepted to be transferred in ETU. She was Parity 2, fetal age at admission was 5 weeks and 3 days. Upon admission, her EVD PCR measured NP 26.3 and GP 32.9. She did not receive monoclonal therapy against Ebola infection due to stock shortage. She received intravenous, artesunate, ceftriaxone, and papaverine. She experienced spontaneous resolution of EVD 18 days after symptom onset and was discharged. At 40 weeks gestation, seven and a half months after EVD recovery, she delivered a healthy female infant, APGAR 10/10/10, weighing 3450 g. Maternal blood, adnexal, and newborn blood samples were RT-PCR negative, and the mother and the baby were discharged after 14 days. At our last follow-up, in June 2023 (2 years, 3 months after delivery), the mother and the baby were in good health. Neonatal survival following spontaneous maternal recovery from EVD in the first trimester of gestation is rare but possible, even in the context of limited clinical resources for treatment.
怀孕会导致母体免疫力出现生理性下降。孕期感染埃博拉病毒病(EVD)与产科并发症相关,因此建议在孕早期进行疫苗接种,但这并非毫无风险。我们描述了母亲自然康复后新生儿的存活情况。这名新生儿的母亲为一名25岁女性,于2020年7月出现症状11天后被收治入埃博拉治疗单元(ETU)。她在症状出现前三天接种了重组水疱性口炎病毒载体埃博拉疫苗(rVSV-ZEBOV),症状出现两天后其实时聚合酶链反应(RT-PCR)结果确诊为EVD和疟疾感染,但她拒绝住院治疗。她在家中接受了口服蒿甲醚-本芴醇、阿莫西林、对乙酰氨基酚、阿苯达唑、奥美拉唑和罂粟碱的治疗。11天后,由于临床病情恶化及出现阴道出血,她最终同意转至ETU。她为经产妇,入院时孕周为5周零3天。入院时,她的EVD PCR检测结果显示核蛋白(NP)为26.3,糖蛋白(GP)为32.9。由于库存短缺,她未接受针对埃博拉感染的单克隆治疗。她接受了静脉注射青蒿琥酯、头孢曲松和罂粟碱的治疗。症状出现18天后,她的EVD实现了自然痊愈并出院。妊娠40周时,即EVD康复七个半月后,她产下一名健康女婴,阿氏评分10/10/10,体重3450克。母亲血液、附件及新生儿血液样本的RT-PCR检测均为阴性,母亲和婴儿在14天后出院。在我们的最后一次随访中,即2023年6月(分娩后2年3个月),母亲和婴儿均健康状况良好。妊娠早期母亲自然康复后新生儿存活的情况虽罕见但有可能发生,即便在临床治疗资源有限的情况下也是如此。